JP2024513048A - Rnaの送達のための組成物及び方法 - Google Patents

Rnaの送達のための組成物及び方法 Download PDF

Info

Publication number
JP2024513048A
JP2024513048A JP2023560598A JP2023560598A JP2024513048A JP 2024513048 A JP2024513048 A JP 2024513048A JP 2023560598 A JP2023560598 A JP 2023560598A JP 2023560598 A JP2023560598 A JP 2023560598A JP 2024513048 A JP2024513048 A JP 2024513048A
Authority
JP
Japan
Prior art keywords
tert
lipid
lnp
composition
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513048A5 (cg-RX-API-DMAC10.html
Inventor
ラムナス,ジョン
ジェレミー マルコフ,グレン
ギリス オルセン,ウィリアム
ダニエル ブリュワー,カイル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rejuvenation Technologies Inc
Original Assignee
Rejuvenation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rejuvenation Technologies Inc filed Critical Rejuvenation Technologies Inc
Publication of JP2024513048A publication Critical patent/JP2024513048A/ja
Publication of JP2024513048A5 publication Critical patent/JP2024513048A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023560598A 2021-03-31 2022-03-30 Rnaの送達のための組成物及び方法 Pending JP2024513048A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163169118P 2021-03-31 2021-03-31
US63/169,118 2021-03-31
PCT/US2022/022642 WO2022212576A1 (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of rna

Publications (2)

Publication Number Publication Date
JP2024513048A true JP2024513048A (ja) 2024-03-21
JP2024513048A5 JP2024513048A5 (cg-RX-API-DMAC10.html) 2025-04-01

Family

ID=83456716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560598A Pending JP2024513048A (ja) 2021-03-31 2022-03-30 Rnaの送達のための組成物及び方法

Country Status (8)

Country Link
US (1) US20220347112A1 (cg-RX-API-DMAC10.html)
EP (1) EP4312942A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024513048A (cg-RX-API-DMAC10.html)
CN (1) CN117396193A (cg-RX-API-DMAC10.html)
AU (1) AU2022246851A1 (cg-RX-API-DMAC10.html)
CA (1) CA3215112A1 (cg-RX-API-DMAC10.html)
IL (1) IL307319A (cg-RX-API-DMAC10.html)
WO (1) WO2022212576A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771213A (zh) * 2023-01-10 2024-03-29 北京剂泰医药科技有限公司 脂质纳米颗粒组合物及其用途
TW202509222A (zh) * 2023-05-08 2025-03-01 美商默沙東有限責任公司 編碼諾羅病毒vp1抗原之多核苷酸及其用途
WO2025049632A1 (en) * 2023-08-29 2025-03-06 Rejuvenation Technologies Inc. Compositions and methods for broad delivery of rna to tissue
WO2025255027A1 (en) * 2024-06-03 2025-12-11 Flagship Labs 114, Inc. Lipid nanoparticles for topical delivery
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026010842A1 (en) * 2024-07-01 2026-01-08 The Trustees Of The University Of Pennsylvania Use of lipid nanoparticle mrna for tert specific cancer immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019188867A1 (ja) * 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質
WO2020051220A1 (en) * 2018-09-04 2020-03-12 The Board of the Regents of the University of Texas System Compositions and methods for organ specific delivery of nucleic acids
US20200215094A1 (en) * 2013-02-22 2020-07-09 The Board Of Trustees Of The Leland Stanford Junior University Compounds, compositions, methods, and kits relating to telomere extension
WO2020142725A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270631B2 (en) * 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200215094A1 (en) * 2013-02-22 2020-07-09 The Board Of Trustees Of The Leland Stanford Junior University Compounds, compositions, methods, and kits relating to telomere extension
WO2019188867A1 (ja) * 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質
US20210023008A1 (en) * 2018-03-27 2021-01-28 Nof Corporation Novel cationic lipid exhibiting improved intracellular dynamics
WO2020051220A1 (en) * 2018-09-04 2020-03-12 The Board of the Regents of the University of Texas System Compositions and methods for organ specific delivery of nucleic acids
WO2020142725A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use

Also Published As

Publication number Publication date
CA3215112A1 (en) 2022-10-06
EP4312942A1 (en) 2024-02-07
WO2022212576A1 (en) 2022-10-06
AU2022246851A1 (en) 2023-10-12
CN117396193A (zh) 2024-01-12
AU2022246851A9 (en) 2023-10-26
EP4312942A4 (en) 2025-03-19
US20220347112A1 (en) 2022-11-03
IL307319A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US12144895B2 (en) Stabilized formulations of lipid nanoparticles
US20220347112A1 (en) Compositions and methods for delivery of rna
EP3595727B1 (en) Lipid nanoparticle formulation
EP3852728B1 (en) Preparation of lipid nanoparticles and methods of administration thereof
EP3917503B1 (en) Methods of preparing lipid nanoparticles
US11744801B2 (en) Methods of making lipid nanoparticles
US12161709B2 (en) Compositions for inducing an immune response against zika virus
JP2022095702A (ja) 脂質ナノ粒子の安定化製剤
JP2024501388A (ja) Rnaの送達のための組成物および方法
HK40101750A (en) Compositions and methods for delivery of rna
JP2025529173A (ja) Rna送達のための組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602